Will Where You Live Determine Access and Coverage of Emerging Anti-Obesity Drugs?
The U.S. Midwest and South regions have higher average obesity rates among adults. What does this mean for access and coverage of prescription drugs for weight loss?
View the Latest: Obesity
Filter
-
-
Obesity Rates Among Children: A Closer Look at Implications for Children Covered by Medicaid
Issue BriefThis brief examines the share of children with obesity, how obesity screening and treatment is covered under Medicaid for children, and what recent changes may mean for Medicaid programs and enrollees in the future.
-
Drugs Used for Weight Loss Could Cost Americans Much More Than People in Peer Countries
News ReleaseIn addition to having the highest obesity rates, the U.S is currently facing significantly higher prices for several major drugs used for weight loss and other health needs, according to a new KFF analysis of the list prices for semaglutide and tirzepatide drugs.
-
How Do Prices of Drugs for Weight Loss in the U.S. Compare to Peer Nations’ Prices?
Issue BriefA class of drugs initially approved for diabetes treatment has captured the public’s and policymakers’ attention as interest in their off-label use for weight loss rises. The weight-loss benefits of these drugs have led to their prescribed use for obesity or overweight treatment.
-
New Weight Loss Drugs Raise Issues of Coverage, Cost, Access and Equity
Event Date:EventNew weight loss drugs, such as Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide), could be transformative for people who struggle with obesity and obesity-related medical conditions, but there are major questions to consider related to insurance coverage, the cost of the drugs, and who has access. On August 4, three experts joined Larry Levitt, executive vice president for health policy at KFF, for a 45-minute “Health Wonk Shop” discussion about the questions surrounding what a new generation of weight loss drugs means for patients and payers.
-
KFF Health Tracking Poll July 2023: The Public’s Views Of New Prescription Weight Loss Drugs And Prescription Drug Costs
FeatureAbout half of adults are interested in taking prescription weight loss drugs. though interest drops when presented with obstacles or drawbacks. Many adults struggle with affording prescription drugs and say there should be more price regulation. Few are aware of provisions in the 2023 Inflation Reduction Act aimed at lowering the drug price for Medicare beneficiaries
-
Poll: Nearly Half of Adults Would Be Interested in Prescription Weight-Loss Drugs, But Enthusiasm Fades Based on Lack of Coverage and Risk of Regaining Weight
News ReleaseNearly half (45%) of the public are at least somewhat interested in taking a prescription weight-loss drug, including many who say they only want to lose a little weight, though many people lose interest when presented with potential financial and medical drawbacks, the latest KFF Health Tracking Poll reveals.
-
How Have Costs Associated With Obesity Changed Over Time?
Issue BriefThis analysis finds that, among people with large employer health plans, those with an obesity diagnosis on average have higher total and out-of-pocket spending than those without an obesity diagnosis. It also examines the cost of common surgical and pharmacological treatments for obesity.
-
What Do We Know about Social Determinants of Health in the U.S. and Comparable Countries?
FeatureSocial determinants, such as individual and community behaviors, economic circumstances, and environmental factors, can influence health costs and outcomes, despite being outside the control of the health system in some respects. This slideshow explores social determinants and health outcomes in the United States and similar countries. The collection looks at income inequality, obesity, educational attainment, and rates of insurance, as well as behaviors such as cigarette and alcohol consumption. Health outcomes, such as disease burden from drug abuse disorders and motor vehicle road injuries, also are examined, along with measures such as years of life lost due to firearms assaults and death rates from accidental poisonings.
-
An Overview of Medicaid Incentives for the Prevention of Chronic Diseases (MIPCD) Grants
Issue BriefThis brief provides an overview of the Medicaid Incentives for the Prevention of Chronic Diseases (MIPCD) grants and highlights key findings from the interim evaluation of the program. The brief also places these grants in context of pre-Affordable Care Act (ACA) Medicaid beneficiary incentive programs and proposed programs of states that are incorporating healthy behavior incentives into Medicaid expansion waivers.